No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DOCS240621P35000
- 7.28
- 0.000.00%
15min DelayTrading May 23 10:22 ET
0.00High0.00Low
0.00Open7.28Pre Close0 Volume0 Open Interest35.00Strike Price0.00Turnover331.30%IV-1.95%PremiumJun 21, 2024Expiry Date7.81Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8555Delta0.0382Gamma3.26Leverage Ratio-0.3515Theta-0.0012Rho-2.79Eff Leverage0.0041Vega
Intraday
- 5D
- Daily
News
Morgan Stanley Maintains Doximity(DOCS.US) With Sell Rating, Maintains Target Price $25
Morgan Stanley analyst Craig Hettenbach maintains $Doximity(DOCS.US)$ with a sell rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 0.0% and a
Should You Think About Buying Doximity, Inc. (NYSE:DOCS) Now?
Doximity(DOCS.US) Director Sells US$300K in Common Stock
$Doximity(DOCS.US)$ Director Cabral Timothy S sold 10,000 shares of common stock on Jun 12, 2024 at an average price of $30 for a total value of $300K.Source: Announcement What is statement of changes
Doximity(DOCS.US) Officer Sells US$900.01K in Common Stock
$Doximity(DOCS.US)$ Officer Bryson Anna sold 30,000 shares of common stock on Jun 12, 2024 at an average price of $30.0002 for a total value of $900.01K.Source: Announcement What is statement of chang
Doximity Insider Sold Shares Worth $300,000, According to a Recent SEC Filing
Timothy S Cabral, Director, on June 12, 2024, sold 10,000 shares in Doximity (DOCS) for $300,000. Following the Form 4 filing with the SEC, Cabral has control over a total of 10,258 shares of the comp
Is It Time To Consider Buying Doximity, Inc. (NYSE:DOCS)?
Doximity, Inc. (NYSE:DOCS), might not be a large cap stock, but it led the NYSE gainers with a relatively large price hike in the past couple of weeks. While good news for shareholders, the comp
Comments
$Doximity(DOCS.US$
from the list. so far its hold that daily support 27.61/27.93 we could see a retest of that montly 28.82/29.26 and maybe 30.40/30.74. if DOCS breaks below, it could test 26.97 or lower 25.98/26.69.
from the list. so far its hold that daily support 27.61/27.93 we could see a retest of that montly 28.82/29.26 and maybe 30.40/30.74. if DOCS breaks below, it could test 26.97 or lower 25.98/26.69.
2
Doximity's high P/E ratio is backed by its promising earnings outlook. Shareholders, confident in future earnings, are holding onto their shares. The company's robust earnings growth and positive future outlook bolster its share price.
2
The telehealth market shone brightly, valued at $128.12 billion. The market is poised for a stellar ascent, forecasted to skyrocket from $142.96 billion in 2023 to a staggering $504.24 billion by 2030. This growth, marked by a robust 19.7% CAGR, highlights the sector’s burgeoning potential, as noted by Fortune Business Insights. The growth of telehealth is significant. It underscores its transformative impact on the future landscape of healthcare.
![]()
$Teladoc Health(TDOC.US$
A...
A...
+2
7
Analysts from William Blair and Raymond James rate DOCS shares as 'Outperform', remaining optimistic about the company's future. They find the solid results and improved guidance range to be a positive step.
Doximity's underpriced shares and forecasted profitability increase its appeal among big growth investors. Its bright future prospects are not entirely factored into its current share price. However, it's recommended to examine the company's finance before investment.
Read more